Phosphodiesterase 10A (PDE10A) inhibition offers a novel mechanism for treating schizophrenia by normalizing dysfunctional striatal activity. This paper details the discovery of MK-8189 (compound 18), a highly potent and selective PDE10A inhibitor, stemming from the optimization of a fragment hit. The optimization addressed liabilities such as poor pharmacokinetic properties, off-target activities, and low solubility, resulting in a compound currently in Phase 2b clinical development for schizophrenia.
Publisher
Journal of Medicinal Chemistry
Published On
Jan 01, 2023
Authors
Mark E Layton, Jeffrey C Kern, Timothy J Hartingh, William D Shipe, Izzat Raheem, Monika Kandebo, Robert P Hayes, Sarah Huszar, Donnie Eddins, Bennett Ma, Joy Fuerst, Gordon K Wollenberg, Jing Li, Jeff Fritzen, Georgia B Mcgaughey, Jason M Uslaner, Sean M Smith, Paul J Coleman, Christopher D Cox
Tags
PDE10A
schizophrenia
MK-8189
inhibition
clinical development
potent inhibitor
Related Publications
Explore these studies to deepen your understanding of the subject.